Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17)
Purpose This randomized trial evaluated the efficacy and toxicity of sequential gemtuzumab ozogamicin (GO) and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia (AML). Patients and Methods Patients (n = 472) age 61 to 75 years were randomly assigned to induction c...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
October 14, 2013
|
| In: |
Journal of clinical oncology
Year: 2013, Volume: 31, Issue: 35, Pages: 4424-4430 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.2013.49.0771 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1200/JCO.2013.49.0771 Verlag, lizenzpflichtig, Volltext: https://ascopubs.org/doi/10.1200/JCO.2013.49.0771 
|
| Author Notes: | Sergio Amadori, Stefan Suciu, Roberto Stasi, Helmut R. Salih, Dominik Selleslag, Petra Muus, Paolo De Fabritiis, Adriano Venditti, Anthony D. Ho, Michael Lübbert, Xavier Thomas, Roberto Latagliata, Constantijn J.M. Halkes, Franca Falzetti, Domenico Magro, José E. Guimaraes, Zwi Berneman, Giorgina Specchia, Matthias Karrasch, Paola Fazi, Marco Vignetti, Roel Willemze, Theo de Witte, and Jean-Pierre Marie |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1757759972 | ||
| 003 | DE-627 | ||
| 005 | 20220819204543.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210512s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.2013.49.0771 |2 doi | |
| 035 | |a (DE-627)1757759972 | ||
| 035 | |a (DE-599)KXP1757759972 | ||
| 035 | |a (OCoLC)1341409082 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Amadori, Sergio |e VerfasserIn |0 (DE-588)123341903X |0 (DE-627)1757759980 |4 aut | |
| 245 | 1 | 0 | |a Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia |b results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17) |c Sergio Amadori, Stefan Suciu, Roberto Stasi, Helmut R. Salih, Dominik Selleslag, Petra Muus, Paolo De Fabritiis, Adriano Venditti, Anthony D. Ho, Michael Lübbert, Xavier Thomas, Roberto Latagliata, Constantijn J.M. Halkes, Franca Falzetti, Domenico Magro, José E. Guimaraes, Zwi Berneman, Giorgina Specchia, Matthias Karrasch, Paola Fazi, Marco Vignetti, Roel Willemze, Theo de Witte, and Jean-Pierre Marie |
| 264 | 1 | |c October 14, 2013 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 12.05.2021 | ||
| 520 | |a Purpose This randomized trial evaluated the efficacy and toxicity of sequential gemtuzumab ozogamicin (GO) and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia (AML). Patients and Methods Patients (n = 472) age 61 to 75 years were randomly assigned to induction chemotherapy with mitoxantrone, cytarabine, and etoposide preceded, or not, by a course of GO (6 mg/m2 on days 1 and 15). In remission, patients received two consolidation courses with or without GO (3 mg/m2 on day 0). The primary end point was overall survival (OS). Results The overall response rate was comparable between the two arms (GO, 45%; no GO, 49%), but induction and 60-day mortality rates were higher in the GO arm (17% v 12% and 22% v 18%, respectively). With median follow-up of 5.2 years, median OS was 7.1 months in the GO arm and 10 months in the no-GO arm (hazard ratio, 1.20; 95% CI, 0.99 to 1.45; P = .07). Other survival end points were similar in both arms. Grade 3 to 4 hematologic and liver toxicities were greater in the GO arm. Treatment with GO provided no benefit in any prognostic subgroup, with the possible exception of patients age < 70 years with secondary AML, but outcomes were significantly worse in the oldest age subgroup because of a higher risk of early mortality. Conclusion As used in this trial, the sequential combination of GO and standard chemotherapy provides no benefit for older patients with AML and is too toxic for those age ≥ 70 years. | ||
| 700 | 1 | |a Ho, Anthony Dick |d 1948- |e VerfasserIn |0 (DE-588)108692477 |0 (DE-627)504904205 |0 (DE-576)19010466X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 31(2013), 35, Seite 4424-4430 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17) |
| 773 | 1 | 8 | |g volume:31 |g year:2013 |g number:35 |g pages:4424-4430 |g extent:7 |a Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17) |
| 856 | 4 | 0 | |u https://doi.org/10.1200/JCO.2013.49.0771 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://ascopubs.org/doi/10.1200/JCO.2013.49.0771 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210512 | ||
| 993 | |a Article | ||
| 994 | |a 2013 | ||
| 998 | |g 108692477 |a Ho, Anthony Dick |m 108692477:Ho, Anthony Dick |d 910000 |d 910100 |e 910000PH108692477 |e 910100PH108692477 |k 0/910000/ |k 1/910000/910100/ |p 9 | ||
| 999 | |a KXP-PPN1757759972 |e 3928120115 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedDisp":"October 14, 2013","dateIssuedKey":"2013"}],"recId":"1757759972","id":{"doi":["10.1200/JCO.2013.49.0771"],"eki":["1757759972"]},"physDesc":[{"extent":"7 S."}],"note":["Gesehen am 12.05.2021"],"relHost":[{"corporate":[{"display":"American Society of Clinical Oncology","role":"isb"}],"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17)Journal of clinical oncology","id":{"issn":["1527-7755"],"zdb":["2005181-5"],"eki":["313116962"]},"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"313116962","origin":[{"dateIssuedKey":"1983","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","dateIssuedDisp":"1983-","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]"}],"pubHistory":["1.1983 -"],"part":{"volume":"31","text":"31(2013), 35, Seite 4424-4430","year":"2013","issue":"35","pages":"4424-4430","extent":"7"},"language":["eng"],"title":[{"title":"Journal of clinical oncology","subtitle":"JCO : an American Society of Clinical Oncology journal","title_sort":"Journal of clinical oncology"}]}],"name":{"displayForm":["Sergio Amadori, Stefan Suciu, Roberto Stasi, Helmut R. Salih, Dominik Selleslag, Petra Muus, Paolo De Fabritiis, Adriano Venditti, Anthony D. Ho, Michael Lübbert, Xavier Thomas, Roberto Latagliata, Constantijn J.M. Halkes, Franca Falzetti, Domenico Magro, José E. Guimaraes, Zwi Berneman, Giorgina Specchia, Matthias Karrasch, Paola Fazi, Marco Vignetti, Roel Willemze, Theo de Witte, and Jean-Pierre Marie"]},"person":[{"display":"Amadori, Sergio","given":"Sergio","role":"aut","family":"Amadori"},{"family":"Ho","role":"aut","given":"Anthony Dick","display":"Ho, Anthony Dick"}],"title":[{"subtitle":"results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17)","title":"Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia","title_sort":"Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia"}],"language":["eng"]} | ||
| SRT | |a AMADORISERSEQUENTIAL1420 | ||